Ameritas Investment Partners’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.15M | Buy |
36,992
+4,708
| +15% | +$338K | 0.08% | 232 |
|
|
2026
Q1 | $2.13M | Buy |
32,284
+94
| +0.3% | +$5.97K | 0.07% | 326 |
|
|
2025
Q4 | $2.05M | Hold |
32,190
| – | – | 0.06% | 325 |
|
|
2025
Q3 | $1.77M | Sell |
32,190
-2,957
| -8% | -$122K | 0.05% | 376 |
|
|
2025
Q2 | $1.16M | Buy |
35,147
+255
| +0.7% | +$8.87K | 0.04% | 564 |
|
|
2025
Q1 | $1.4M | Sell |
34,892
-703
| -2% | -$32.3K | 0.05% | 475 |
|
|
2024
Q4 | $1.67M | Sell |
35,595
-122
| -0.3% | -$6.34K | 0.05% | 415 |
|
|
2024
Q3 | $1.89M | Buy |
35,717
+385
| +1% | +$21.5K | 0.06% | 355 |
|
|
2024
Q2 | $1.91M | Buy |
35,332
+4,329
| +14% | +$261K | 0.07% | 315 |
|
|
2024
Q1 | $2.17M | Buy |
31,003
+21,622
| +230% | +$1.67M | 0.07% | 305 |
|
|
2023
Q4 | $783K | Buy |
9,381
+127
| +1% | +$4.6K | 0.03% | 681 |
|
|
2023
Q3 | $273K | Buy |
9,254
+1,563
| +20% | +$52.1K | 0.01% | 1001 |
|
|
2023
Q2 | $251K | Buy |
7,691
+1,254
| +19% | +$46.4K | 0.01% | 1000 |
|
|
2023
Q1 | $227K | Hold |
6,437
| – | – | 0.01% | 1021 |
|
|
2022
Q4 | $272K | Hold |
6,437
| – | – | 0.01% | 969 |
|
|
2022
Q3 | $311K | Buy |
6,437
+292
| +5% | +$14.1K | 0.01% | 874 |
|
|
2022
Q2 | $241K | Hold |
6,145
| – | – | 0.01% | 967 |
|
|
2022
Q1 | $226K | Hold |
6,145
| – | – | 0.01% | 1114 |
|
|
2021
Q4 | $280K | Hold |
6,145
| – | – | 0.01% | 1028 |
|
|
2021
Q3 | $220K | Buy |
6,145
+490
| +9% | +$14.4K | 0.01% | 1132 |
|
|
2021
Q2 | $112K | Hold |
5,655
| – | – | ﹤0.01% | 1653 |
|
|
2021
Q1 | $132K | Hold |
5,655
| – | – | 0.01% | 1492 |
|
|
2020
Q4 | $118K | Hold |
5,655
| – | – | 0.01% | 1480 |
|
|
2020
Q3 | $122K | Buy |
5,655
+970
| +21% | +$22.7K | 0.01% | 1311 |
|
|
2020
Q2 | $110K | Hold |
4,685
| – | – | 0.01% | 1355 |
|
|
2020
Q1 | $55K | Hold |
4,685
| – | – | ﹤0.01% | 1595 |
|
|
2019
Q4 | $50K | Hold |
4,685
| – | – | ﹤0.01% | 1923 |
|
|
2019
Q3 | $53K | Hold |
4,685
| – | – | ﹤0.01% | 1850 |
|
|
2019
Q2 | $53K | Buy |
4,685
+1,038
| +28% | +$10K | ﹤0.01% | 1875 |
|
|
2019
Q1 | $30K | Hold |
3,647
| – | – | ﹤0.01% | 2153 |
|
|
2018
Q4 | $23K | Hold |
3,647
| – | – | ﹤0.01% | 2259 |
|
|
2018
Q3 | $36K | Hold |
3,647
| – | – | ﹤0.01% | 2173 |
|
|
2018
Q2 | $30K | Hold |
3,647
| – | – | ﹤0.01% | 2276 |
|
|
2018
Q1 | $26K | Hold |
3,647
| – | – | ﹤0.01% | 2280 |
|
|
2017
Q4 | $30K | Hold |
3,647
| – | – | ﹤0.01% | 2225 |
|
|
2017
Q3 | $54K | Hold |
3,647
| – | – | ﹤0.01% | 1847 |
|
|
2017
Q2 | $44K | Buy |
3,647
+811
| +29% | +$11.3K | ﹤0.01% | 1987 |
|
|
2017
Q1 | $36K | Buy |
+2,836
| New | +$33.1K | ﹤0.01% | 2046 |
|
Other funds holding CYTK
ACA
Ameritas Investment Partners's CYTK Position: Q2 2026 in Review
Ameritas Investment Partners increased its Cytokinetics (CYTK) stake by 15% in Q2 2026, buying an estimated $338K and bringing the position to 36,992 shares worth $3.15M. The position accounts for 0.08% of the portfolio, ranked #232.
Ameritas Investment Partners first reported a position in CYTK in Q1 2017 and has held it in 38 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Ameritas Investment Partners held 36,992 shares of Cytokinetics worth $3.15M as of Q2 2026.
- Ameritas Investment Partners bought 4,708 Cytokinetics shares in Q2 2026, an estimated $338K.
- Cytokinetics made up 0.08% of Ameritas Investment Partners's portfolio in Q2 2026, its #232 holding.
- Ameritas Investment Partners first reported a position in Cytokinetics in Q1 2017 and has held it in 38 quarters since.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.